METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Navy beans take on fatty liver: a diet swap put to the test
Disease control Not yet recruitingThis trial tests whether replacing some of the usual diet with navy beans — without changing total calories — is a practical and acceptable way to help manage metabolic dysfunction-associated steatotic liver disease (MASLD) in adults with intermediate-stage liver fibrosis. Forty …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a single gene therapy injection reverse fatty liver disease?
Disease control Not yet recruitingThis trial tests an experimental gene therapy called VV-14303 for people with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity and diabetes. The therapy uses a harmless virus to deliver a protein (FGF21) that may improve liver h…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1, PHASE2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a tailored diet make a MASH drug work better?
Disease control Not yet recruitingThis study tests whether adding a Mediterranean-style meal delivery program to resmetirom therapy improves liver health more than resmetirom alone. It involves 120 adults with non-cirrhotic MASH who are starting resmetirom. Participants either receive the drug plus 10 medically t…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE4 • Sponsor: City University of New York • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New injections aim to melt liver fat in MASH patients
Disease control Not yet recruitingThis clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 we…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to melt liver fat and stop scarring in MASH patients
Disease control Not yet recruitingThis study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot aims to reverse liver scarring in MASH patients
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Healthy volunteers test new MASH drug in early safety trial
Knowledge-focused Not yet recruitingThis early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC